<DOC>
	<DOCNO>NCT01326273</DOCNO>
	<brief_summary>The investigator assess whether infusion autologous CMV-specific T-cells time CMV reactivation posttransplant prevent worsen CMV virus reactivation posttransplant level warrant therapy antiviral drug ( objectively assess look CMV virus copy number ) .</brief_summary>
	<brief_title>Autologous Cytomegalovirus ( CMV ) Specific CD8+ T Cells Treatment CMV Reactivation</brief_title>
	<detailed_description>Allogeneic Hematopoietic Stem Cell transplantation ( allo-SCT ) remain curative approach number patient hematological malignancy . However , use allo-SCT expose patient prolong period immunosupression time viral infection significant cause morbidity mortality . Human cytomegalovirus ( CMV ) infection reactivation still represent one important lifethreatening complication immunocompromised patient . Prophylaxis early treatment antiviral drug CMV reactivation reduce mortality relate complication . However , antiviral drug many side-effects costly . Furthermore , CMV infection refractory antiviral treatment alloSCT associate high mortality . A number study show efficacy select Tcells virus donor infuse recipient ( adoptive transfer immunity ) prevent treat CMV reactivation . However approach relies donor preexisitng immunity CMV ( 50 % healthy population CMV seronegative therefore preexist immunity CMV ) . We propose alternative approach collect CMV specific Tcells seropositive recipient prior transplantation ; autologous CMV specific T cell infuse back recipient time CMV reactivation post-transplant . This approach especially relevant donor CMV seronegative unavailable follow use cord blood transplant memory T cell response CMV .</detailed_description>
	<criteria>1 . Patients must receive allogeneic stem cell transplant donor , treatment haematological malignancy . 2 . HLAA0201 positive one allele 3 . CMV seropositive 4 . The patient must willing capable donating lymphocyte CMVspecific CD8+ T cell selection use apheresis technique 5 . The patient must complete remission evidence circulate blast malignant cell 6 . Patient must fit undergo leukapheresis 7 . Patients must sign informed consent form undergo LP prior alloSCT Indications infusion autologous CMV specific CD8+ Tcells : Therapeutic : CMV disease follow allogeneic stem cell transplantation Preemptive : CMV reactivation ( CMV DNA PCR ) autologous CMV specific CD8+ Tcells must infuse patient later 72 follow CMV reactivation . Steroids withdraw least 1 week infusion CMVspecific CD8+ Tcell Patients must sign informed consent form infusion autologous CMV specific CD8+ Tcells 1 . Patient CMV seronegative 2 . No informed consent 3 . Patient positive time LP one follow infectious agent : HIV , HBV , HCV , Syphilis , HTLV 1 2 4 . Patient circulate leukemic blast time LP Exclusion criterion infusion autologous CMV specific CD8+ T cell : Severe GvHD ( grade IIIIV ) require full dose immunosuppressive treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>CMV</keyword>
	<keyword>cytomegalovirus</keyword>
	<keyword>autologous</keyword>
	<keyword>leukemia</keyword>
	<keyword>hematological malignancy</keyword>
	<keyword>stem cell transplantation</keyword>
	<keyword>CMV reactivation</keyword>
	<keyword>adoptive therapy</keyword>
</DOC>